Moderna files for FDA authorisation for updated COVID-19 vaccine
June 23, 2023Research and Development COVID-19, FDA, Immunology, Moderna, Vaccine
Biotechnology company Moderna has announced that it has completed submission of a regulatory application to the US Food and Drug …
XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets
June 23, 2023Sales and Marketing Cancer, Oncology, Xoma, acquisition, oncology
US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone rights for two assets from …
GSK settles first Zantac lawsuit due for trial in US
June 23, 2023Medical Communications Cancer, GSK, Pharmacy, Zantac, lawsuit
UK-based pharmaceutical and biotechnology company GSK has reached a settlement with a US man who claims the drugmaker’s heartburn medicine …
Lupin Healthcare launches Beclu carbon neutral inhalers for asthma treatment
June 22, 2023Research and Development Asthma & COPD, Beclu, Lupin Healthcare, asthma, carbon neutral, inhaler
UK-based subsidiary of Lupin Limited, Lupin Healthcare, has announced the UK launch of its carbon neutral pressurised metered dose inhalers …
FDA approves new medicines to treat paediatric type 2 diabetes
June 22, 2023Medical Communications Diabetes, FDA, Synjardy, jardiance, paediatrics, type 2 diabetes
The US Food and Drug Administration (FDA) has announced that it has approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin …
Hyloris enrols first patient in four-arm clinical trial
June 22, 2023Research and Development Genito-Urinary system, Hyloris, bladder pain, clinical trial, cystitis
Belgian specialty biopharmaceutical company Hyloris has announced that it has enrolled the first patient in its four-arm interstitial cystitis/bladder pain …
Zymeworks to open new EU HQ in Dublin, Ireland
June 22, 2023Business Services Dublin, Oncology, Zymeworks, headquarters, regulatory affiars
Canadian biotech company Zymeworks has announced plans to open its new Clinical and Regulatory EU headquarters in Dublin, Ireland. Zymework …
Eli Lilly to acquire DICE Therapeutics for immunology innovations
June 21, 2023Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology
Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …
GSK shares positive data for RSV vaccine
June 21, 2023Research and Development GSK, Immunology, RSV, Vaccine, clinical trial
GSK have announced new positive data from the AReSVi-006 phase 3 trial which assessed the efficacy of a single dose …
FDA approves Pfizer’s HRR mCRPC drug
June 21, 2023Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer
US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …
PharmaTher and Vitruvias sign collaboration agreement to commercialise ketamine-based treatment in the US
June 21, 2023Medical Communications Ketamine, Neurology, PharmaTher, Vitruvias, commercialisation
Specialty pharmaceutical companies, Canadian PharmaTher and US-based Vitruvias, have entered into a commercialisation partnership to bring Ketarx products to the …
Sirnaomics advances isSCC candidate into late-stage clinical development
June 20, 2023Research and Development FDA, Oncology, Sirnaomics, clinical trial, isSCC
Global RNA therapeutics biopharmaceutical company Sirnaomics has announced that it has advanced its Squamous Cell Carcinoma in situ (isSCC) candidate …
Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership
June 20, 2023Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership
Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …
GSK announces extension of FDA’s review for momelotinib
June 20, 2023Medical Communications FDA, GSK, Oncology, momelotinib, new drug application
GSK has announced that the US Food and Drug Administration (FDA) has extended its review period for the new drug …
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
June 20, 2023Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera
Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …
Immodulon appoints Josefine Roemmler-Zehrer as chief medical officer
June 20, 2023Immodulon, Josefine Roemmler-Zehrer, appointment, chief medical officer
Cancer immunotherapy company Immodulon has announced that it has appointed Josefine Roemmler-Zehrer as chief medical officer, bringing with her vast …
Scientists develop 3D printed pills for time-controlled release
June 19, 2023Research and Development 3d printed pills, 3d printing, Max Planck Insititute, Pharmacy, University of California
A team of scientists at the Max Planck Institute (MPI) for Informatics, Germany, and the University of California, US, have …
Vaxxas opens manufacturing facility for needle-free vaccine patch
June 19, 2023Research and Development Immunology, Vaxxas, manufacturing, needle-free vaccines, vaccines
Clinical stage biotech company Vaxxas has announced that it is opening a biomedical manufacturing facility in Brisbane, Australia, for the …
ImmuPharma initiates phase 2/3 clinical trial for lupus treatment
June 19, 2023Research and Development Avion Pharmaceuticals, ImmuPharma, Immunology, Lupus, clinical trial
ImmuPharma has announced that it will commence a phase 2/3 adaptive clinical trial of P140 (Lupuzor) in patients with systemic …
Rani Therapeutics’ oral ‘robotic pill’ delivers injection trans-enterically
June 19, 2023Medical Communications Osteoporosis, Rani Therapeutics, injection, osteoporosis, robotic pill, robotics
US Rani Therapeutics, a clinical-stage biotherapeutics company, has reported new results from its phase 1 trial into the RaniPill capsule …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
